Medical Technology

@xconomy.com 3 years ago

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 3 years ago

Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More

@xconomy.com 3 years ago

Two Days, Six IPOs, and $1B Raised for Biotech Research & More

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines

@xconomy.com 4 years ago

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning